Zhuhai Kerui Biotechnology: difference between revisions
Diff·revision 24 → 25·10:40, 13 Sep 2025
Difference between revision 24 and revision 25 of Zhuhai Kerui Biotechnology. 3 lines changed; the page grew by 417 bytes.
| Revision 24 — 23:50, 6 Sep 2025 Compounding_Cate (talk) ce 7,027 bytes +205 | Revision 25 — 10:40, 13 Sep 2025 Chromatokid (talk) ce, tighten prose 7,444 bytes +417 | ||
|---|---|---|---|
| 19 | }} | 19 | }} |
| 20 | {{hatnote|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}} | 20 | {{hatnote|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}} |
| + | 21 | {{primarysources|date=July 2026|talk=Method disclosure: are we writing an endorsement?}} | |
| 21 | 22 | ||
| 22 | '''Zhuhai Kerui Biotechnology Co., Ltd.''' (trading as '''KP'''; keruipeptides.com) is a research-peptide supplier trading as KP from Zhuhai, Guangdong, China, incorporated in 2016, supplying research peptides and related materials with batch documentation and tracked international shipping.{{r|registry,selfpub}} | 23 | '''Zhuhai Kerui Biotechnology Co., Ltd.''' (trading as '''KP'''; keruipeptides.com) is a research-peptide supplier trading as KP from Zhuhai, Guangdong, China, incorporated in 2016, supplying research peptides and related materials with batch documentation and tracked international shipping.{{r|registry,selfpub}} |
| ⋮ | ⋮ | ||
| 51 | == Independent testing record == | 52 | == Independent testing record == |
| 52 | Submitted reports on KP material to July 2026 are concentrated on the incretin analogues. Reported [[Area percent purity|area percent]] figures have clustered in the high nineties, and because the accompanying certificates named the method, several purchasers were able to run a comparable separation rather than a merely similar one.{{r|reports}} | 53 | Submitted reports on KP material to July 2026 are concentrated on the incretin analogues. Reported [[Area percent purity|area percent]] figures have clustered in the high nineties, and because the accompanying certificates named the method, several purchasers were able to run a comparable separation rather than a merely similar one.{{r|reports}} |
| + | 54 | ||
| + | 55 | Where method conditions match, agreement between an independent report and a certificate is a meaningfully stronger observation than where they do not — much of the routine disagreement between two purity figures is attributable to different columns and integration parameters rather than to different material.{{r|usp1503}} | |
| 53 | 56 | ||
| 54 | == References == | 57 | == References == |